The RESOLVE trial, sponsored by Catherine Bollard at Children's National Research Institute, is a Phase I dose-escalation study aimed at evaluating the safety of tumor-associated antigen-specific cytotoxic T lymphocytes (TAA-T) in patients with very high-risk hematopoietic malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trial is currently recruiting participants and is positioned to address a significant unmet medical need in a patient population with limited treatment options. The successful demonstration of safety and potential efficacy could lead to further development and commercialization opportunities in the immunotherapy space, particularly for hematological malignancies. Given the competitive landscape, including existing CAR-T therapies, the differentiation of TAA-T based on multi-antigen targeting may provide a strategic advantage. Stakeholders should monitor the trial's progress closely for insights into market viability and potential partnerships.